POI Mission

Preventive Oncology International is dedicated to blending humanitarian care with scientific discovery.

The goal of POI is to conduct research, provide education and work toward the prevention, and early detection of cancer through the development of new screening technologies that will prevent cervical cancer and other cancers in the United States and worldwide.

POI provides cervical cancer screening to women throughout the world while conducting medical research on early detection and prevention.  We develop, test and evaluate new methods of making cervical cancer testing more accurate and more reliable, as well as cheaper and easier to use.  Current methods of testing are costly and require a complex medical infrastructure in order to successfully detect cervical cancer and pre-cancers. In underserved populations around the world, the infrastructure and support does not exist, so women go through life without ever getting screened, which leads to late detection of cancer and subsequent unnecessary deaths.

Fact: Cervical cancer prevention in women is an important health strategy in the United States and worldwide. There are approximately 530 million cases of cervical cancer diagnosed each year in the world, and in 2008, 275,000 deaths. It is the third cause of death from cancer in women and the greatest cancer killer of women under the age of 50 years. It kills women at the height of their productive lives often when they still have children at home.

Preventive Oncology International’s research will lead to the development of low-cost screening and treatment algorithms for cervical cancer. It will also provide technologies and methods to increase access to care for women in underserved parts of the United States and areas of the world where screening programs do not exist or do not reach the women most in need. For example, using a POI developed self-collection kit, women can collect their own sample and then send the specimen to a laboratory for quicker results without the need for an examination to be performed by a health care professional.

POI History

Preventive Oncology International, Inc. (1997- present)

Preventive Oncology International, Inc. (POI) was established in 1997, and became the international research arm of the Division of Gynecologic Oncology in the Department of Gynecology and Obstetrics at The Cleveland Clinic in Cleveland, Ohio. On the 29th of July 2008, with the retirement of it’s founder Jerome L Belinson MD from clinical practice at the Cleveland Clinic, POI became its own 501(c)3. In 2010 a formal legal affiliation was established with the Women’s Health Institute at the Cleveland Clinic.

To date POI has conducted research in China, Malaysia, Mexico, Peru, USA., Dominican Republic and collaborated with research groups working in India, Haiti, Kenya, Brazil, The Netherlands, Belgium, and the USA.

Twenty U.S. based students, residents, and fellows have done research with POI. Their participation and the studies’ data were used to complete educational requirements and contributed to several students earning their master’s degrees in public health (MPH) and a Doctorate in Epidemiology (PhD). An equal number of graduate students from China have also worked with POI in order to complete advanced degrees.

POI has had consistent guiding principles:

  • To blend clinical care with our research, particularly in medically underserved communities.
  • To always have a POI staff or a devoted collaborator on site, but primarily work with an “in-country” research team plus local (community) caregivers.
  • Raise funds for POI per project.
  • Conduct only investigator initiated (designed) clinical trials.
  • Work with researchers as a functional team, focused on the design and quality of the research, rather than the order of manuscript authorship.

POI is a simple organization that makes things happen efficiently; always conducting our research carefully with the highest respect and gratitude for the women who have consented to receive our care and thus participated as “subjects” in our clinical trials. Over the past 27 years we have worked side-by-side with hundreds of physicians, nurses, clinical assistants, and graduate students; we are indebted to the many people (and their families) who have worked in our clinical investigations, and we genuinely hope they feel their participation provided value for their lives and that they felt the respect and gratitude we had for them for joining us in our work.

An overwhelming feeling of decency and benevolence has been experienced by our workforce each time we entered a rural village and realized: the only reason the women were going to receive medical care was “because we were there.”

Currently POI is energized and charged with a new mission: do everything in our power to support our colleagues and help facilitate the completion of their work on PAVE which is expected to require 2.5 years.PAVE

PAVE is a novel strategy for cervical cancer screening and prevention targeting low-income and hard to reach populations. It integrates self-collection for the human papillomavirus and A.I. assisted visual evaluation to provide a risk of having high grade cervical pre-cancer or cancer. PAVE’s current accomplishments include bringing together personnel from 4 continents (9 countries plus the USA) to achieve the goal of preventing cervical cancer globally.  The personnel include epidemiologists, physicians, statisticians, public health specialists, laboratory scientists, AI specialists, and engineers focused on working together to address the fact that 600,000 women develop cervical cancer every year, and 300,000 die from the disease. The women who are most at risk are those who were born before the HPV vaccine was available, were unable to get the vaccine prior to infection, or have no access to the vaccine.  Over the past 7 years using the latest developments in Human Papillomavirus technologies (in part developed by PAVE) and AI assisted visual examination (refined by PAVE), a novel low cost highly accurate screening strategy has been developed for resource-limited settings. Now with the finish line in site, the NIH funding has been eliminated as of June 2025. To complete the work the algorithm needs to be validated against current models and their cost-effectiveness demonstrated so world-wide acceptance and implementation can occur.

POI is planning to continue its work and to support other researchers with the intent to prevent cervical cancer globally.  We are currently raising funds to complete the next phase of the PAVE project and expand the project to national and international sites that POI has worked in over the past two decades.  About PAVE 

POI Purpose and Vision

The challenges of cervical cancer prevention and early detection.

Mortality from cervical cancer is uncommon in developed countries. In 1989 in the United States, mortality from cervical cancer was only 3.1 per 100,000 women per year. In part, the low mortality from cervical cancer can be attributed to early detection of and elimination of precancers. In developed countries this has been realized by periodic cytologic screening with Papanicolaou smears. Theoretically, periodic cytologic screening can prevent 90% of invasive squamous cancers of the cervix.

The remarkable decline in mortality from cervical cancer seen in developed countries has not been seen in underdeveloped countries. Worldwide, cervical cancer remains the third most common malignancy in both incidence and mortality, with close to a half a million cases diagnosed, and 230,000 deaths each year. It is the greatest cause of death from cancer in women in the developing world and the greatest cancer killer of young women (< age 50). It kills women at the height of their productive lives often when they still have children at home. Though periodic cytologic screening could decrease these numbers greatly, it has not been adopted worldwide because it is expensive and because a cytology based screening system requires a significant healthcare infrastructure.

To limit expense and the need for a complex healthcare infrastructure, we have been studying various screening technologies looking to find combinations or single tests that are sensitive and specific enough such that women who test positive can be treated for precancer of the cervix without resorting to histologic (biopsy) confirmation of the diagnosis.  POI is developing, testing and evaluating new methods to make cervical cancer screening  more accurate and more reliable as well as cheaper and easier to implement.  If developments continue on their current path , POI will  assist in the creation of an inexpensive self-sampling test kit so that individual women can perform a self-examination and then send the sample to a laboratory for quicker results without the need for an examination to be performed by a health care professional.

This research will lead to the development of low cost screening and treatment algorithms for cervical cancer. Importantly, it will also provide increased access to care for women in underserved parts of the United States and areas of the world where screening programs do not exist or do not reach the women most in need.

POI conducts primarily investigator initiated research.  Research questions are developed by POI and its colleagues, then funding is sought to support the research.  Funders may have related research questions they they want to investigate, and collaboratively a protocol is written to meet the objectives of POI and its funders

Objectives of Past Projects

  • To develop models using community based participatory research methodologies that will allow todays screening technologies to reach the under-served.
  • To provide cost and time efficient research programs that are able to provide vital clinical research data for industries with technologies related to cancer prevention and early diagnosis.
  • To teach the low-cost screening and diagnostic algorithms so they may continue in these underserved areas when demonstrated to be successful.
  • To provide experiences in international public health for students, residents, fellows and other interested physicians.

POI Thanks

It is essential to recognize that due to the “in-country” model we followed, there are a few individuals who allowed us to enter their lives, and without whose guidance and expertise the past 27 years would never have occurred.

China (27 years):

We will be forever grateful that my letter to Zhi Wei Dong PhD, the Director (in 1997) of the Cancer Institute/Hospital in Beijing of the Chinese Academy of Medical Sciences was handed to Professor You-Lin Qiao MD PhD, the Chief of Epidemiology at CICAMS. This most critical step allowed EVERYTHING that followed to occur.

Dr Qiao and the Chair of Gynecologic Oncology, Dr Wen Hua Zhang were the principal organizers and clinical facilitators of all of our trials for the first decade. As stated earlier, many other critical personnel: clinicians, pathologists, cytologists, laboratory technicians, nurses, clinical assistants, statisticians, administrative staff from Beijing, and local clinicians and staff from the multitude of villages in the many Provinces where we conducted research helped form our team.

Each “in-country” organizational charts can become very complex with the multitude of individuals whose work was essential to each study’s success. For our initial trial in China “SPOCCS I” (Shanxi Province Cervical Cancer Screening Study) our research team consisted of 62 persons, both US and Chinese.

In 2008-9 we moved the center of our work in China to Shenzhen, Guangdong Province, in Southern China. The Peking University, Shenzhen Hospital (PUSH), was the only hospital in the Peking University Hospital System located outside of Beijing (Peking). The leader of the Department of Obstetrics and Gynecology for more than 20 years became the most important person for our work in China for the next 15 years. Professor Ruifang Wu MD as a strong leader, and a clinician genuinely interested in research and education became our leader and dear friend. Led by Professor Wu, we traveled as a team to provide care for tens of thousands of women in our clinical trials.  There 5 other individuals in Shenzhen, whose work, time, and commitment need special mention: Hui Du MD (clinician); Xinfeng Qu MD (Steve, administrator and great friend); Guixiang Wang MD (clinician); Chun Wang MD (Pathologist); and Yuen Chen MD who as leader of PUSH facilitated local politics and the support from the Shenzhen Female Doctors Association for our work.  It is also critical to mention the guidance both clinical and political our work received from the esteemed Professor and Chair of the Department of Obstetrics and Gynecology at Peking University People’s Hospital in Beijing Professor  Lihui Wei MD.

Our work introduced HPV testing and liquid based cytology into China for cervical cancer screening. It is also noteworthy that Professor Qiao translated our foundational work into expanded clinical care guidelines by forming the Chinese Cervical Cancer Consortium which eventually covered most provinces in China. In regard to continuing education, Professor Wei did the same, in leading the creation of the Chinese Society of Colposcopy and Cervical Pathology (related to the ASCCP in the USA).

Mexico (10 years):

The singular individual most responsible for contacting the communities (including indigenous populations), negotiating the politics, setting up the labs, and the movement of supplies was Christine Enerson, MD.  Dr Enerson also graciously participated in our clinical work.

Peru (3 years):

Glorious Peru was the second site for our progressive development of our community-based screening models: first in Manchay, a squatters village on the outskirts of Lima; and then in seven villages in the lower Amazonian region in Iquitos. Carlos Villejos Solgeron, MD., and his daughter Majo (Maria Jose Villejos) were our key facilitators. We are indebted to the de Osma family for their support and hospitality in Peru. We are especially grateful to our dear friend from Mexico, Jorge Salmeron, MD. MPH. PhD, who joined our research team and most critically guided us through the nuances of South American politics and Spanish culture keeping us on track for our work.

Dominican Republic (1 year)

The site of our initial work with optical coherence tomography. All was organized and made possible by Luis Rojas Grullón MD.

POI Staff

POI Executive Staff

POI Staff and key team members

From the Cleveland Clinic, University Hospitals in Cleveland, Ohio we have been joined by students, residents, many gynecologic oncology fellows, and staff (especially from the Department of Pathology), all contributing to the success of our work.

Over the past 27 years, the POI staff, underwent just a few changes, but has always been limited to those vital to our work.

Current:

  • Jerome L. Belinson MD. Founder and President of Board
  • Robert G. Pretorius MD. Founder and Vice President of Board
  • Bin Yang MD PhD. Pathologist and Secretary/Treasurer of the Board
  • Shane Millette – Chief Financial Officer
  • Nancy Tresser Lipko MD – administrative coordinator (US based)
  • XinFeng Qu MD – administrative coordinator (China based)

Past Years:

  • Mary Mohr MHA, MSN, RN – Executive Director for 10 years
  • Monique Washington RN – first administrative/clinical coordinator
  • Donna Fife RN – second administrative/clinical coordinator (China based)
  • Guixiang Wang MD – field coordinator (China based)
  • Suzanne E. Belinson MPH. PhD. Epidemiology, Biostatistics, and board member
  • Sarah Hayes – Bookkeeper
  • Dennis Siciliano – Legal Council

POI Funding Sources

POI conducts primarily investigator initiated research.  POI its colleagues develop research questions, and funding is then sought  to support the investigation.  Funders may have related research questions that they want to investigate, and collaboratively a protocol is written that achieves the objectives of POI and the funding source.

POI has received funding in kind, services and/or donations from the following sources:

  • Taussig Cancer Center Cleveland Clinic Foundation
  • Cancer Institute/Hospital, Chinese Academy of Medical Sciences
  • The National Institutes of Health
  • Merck Corporation
  • Terry Fox Foundation
  • Carl Zeiss Inc.
  • Transamerica Corporation
  • Digene Corporation (now Qiagen)
  • Cytyc Corporation (now Hologic Inc.)
  • Hologic Inc.
  • Optical Biopsy Tech. LLC.,
  • Molecular Diagnostics Inc.
  • Rotary International
  • The State of Ohio – Ohio Technology Action Fund Grant
  • The Imalux Corporation
  • Third Wave Technologies (now Hologic Inc.)
  • Genetel Pharmaceuticals Ltd.
  • Gen-Probe, Inc. (Hologic Inc.)
  • BGI Shenzhen
  • Peking University Shenzhen Hospital
  • Becton Dickinson Company
  • Shenzhen Female Doctors Association
  • Private donors

Thank you!!

Project Funding

This is a partial list containing most, but not limited to:

  • Our initial trip for our first pilot trial in China in 1997 was funded by a generous gift from Jane Horvitz in Cleveland, Ohio. It will always be appreciated and cherished.  Her donation represents the initial funding that endorsed a local non-profit organization to continue its global work for almost three decades.
  • SPOCCS —Shanxi Province Cervical Cancer Screening Study:  A Cross-Sectional Comparative Trial of Multiple Techniques to Detect Cervical Intraepithelial Neoplasia. Jerome L Belinson P.I. Funding Taussig Cancer Center and Multiple industries (including product from Digene Corporation) $268,000 1998-1999.
  • Multiple small private donations, with special recognition to long term support and counsel from Mr. Anthony Yen (Cleveland, Ohio)
  • SPOCCS II — Shanxi Province Cervical Cancer Screening Study II: A Comparative trial of Multiple Techniques to Detect Cervical Intraepithelial Neoplasia. Jerome L. BelinsonP.I. Funding Molecular Diagnostics Inc., and P.O.I., $876,071.17   0ct. 2000-June 2002. (IRB- 3822)
  • MECCS Pilot –Mexican Cervical Cancer Screening Study–Pilot, Jerome L. Belinson P.I.-Funding P.O.I., and “Test for Life Fund” Morelia, Mexico.  Budget- $185,358. (IRB- 4760).
  • MECCS I —- Mexican Cervical Cancer Screening Study. Jerome L. Belinson P.I.- Rotary International -$90,000, 2001-2004.
  • OCT –Study of the Diagnostic Efficacy of Optical Coherence Tomography in the Management of Pre- invasive and Invasive Cancer of the Uterine Cervix and the Vulva. Funding from Imalux Corp. $36,000, Jerome L. Belinson P.I. (IRB- 4935)
  • E2 — Multicenter Clinical Study Assessing the Equivalence of the InPath e2 Cervical Cell Collector to a Standard Endocervical Brush in a Patient Population Including Both Patients with a Recent “normal” Pap Screening Diagnosis and Patients Returning for Colposcopy/Biopsy, $82,000,Jerome L. Belinson P.I. (IRB- 4211).
  • CVX – Multicenter Study of the Inpath CVX –Assay (Molecular Biomarker) in the Diagnosis of Pre-Invasive Carcinoma of the Uterine Cervix. Funding Molecular Diagnostics Inc. $82,608. Jerome L. Belinson P.I.  (IRB- 4793) In addition a laboratory is being established at Edison Biotec to allow further expansion of our Ovarian as well as our Cervical Cancer early diagnosis work.
  • Survey – Women’s Experience with the self-test for HPV – A Questionnaire Investigating the Understanding of Cervical Cancer, HPV, and Cultural Differences in Acceptance of self-testing; P.I. Suzanne E. Belinson MPH, Co-investigator JL Belinson.  Funding from Preventive Oncology International $10,000. (Component IRB-3822).
  • Development of Optical Coherence Tomography for the Management of Pre-invasive and Invasive Cancers of the Cervix and Vulva. Ohio Technology Action Fund $542,000 Granted with Matching Funds of $271,000 from Investors of Imalux Corporation. Jerome L. Belinson P.I. (July 2002).
  • NIH Contract – Pilot evaluating self-collection devices for HPV testing.  JL Belinson (March 2006) $24,975.00.
  • SPOCCS III – Detection of a Broad Spectrum of HPV Types and Associated Cervical Cancer and Intraepithelial Neoplasia in Chinese Women Between the Ages of 15 and 55 in 5 Sites in China: A Community Based Epidemiologic Study. JL Belinson P.I. Funding Merck $1,450,000.00 and Preventive Oncology International $111,830.26
  •  PUSH-OCT and GUIZHOU OCT – “Study of the diagnostic efficacy of “real time” optical coherence tomography (oct) in the management of pre-invasive and invasive neoplasia of the uterine cervix”  and “study of the diagnostic efficacy of “real-time” optical coherence tomography (OCT) as an adjunct to unaided visual inspection with acetic acid (v) for the diagnosis of pre-invasive and invasive neoplasia of the uterine cervix” $50,000  and $65,000  respectively, 2005-2008 Imalux Corporation. JL Belinson PI
  • MECCS II – Mexican Cervical Cancer Screening Study II – Funding $450,000 from Gen-Probe Inc., additional support from the Secretary of Health State of Michoacan, Mexico, Qiagen Corporation, and Preventive Oncology International Inc, and the Cleveland Clinic. JL Belinson PI 2009-2010
  • MECCS II Follow-up — $25,000 – Preventive Oncology International, Inc. 2009-2010
  • SHENCCAST I – The Shenzhen Cervical Cancer Screening Trial I, 2008-2009, funding from Ministry of Health Shenzhen China, TriPath Inc., and $130,000 from Gen-Probe Inc., Beijing Genomics Institute. PI Ruifang Wu , JL Belinson Co-PI
  • SHENCCAST II – The Shenzhen Cervical Cancer Screening Trial II, 2009-2010. Funding $1,500,000 from Hologic Inc. additional support Shenzhen Female Doctors Association, Preventive Oncology International, Inc., Beijing Genomics Institute.   JL Belinson PI
  • SHENCCAST III – Unrestricted Grant from Hologic Inc. – Applied to an Evaluation of Cervista 16/18 HPV Assay – $460,650.00 JL Belinson PI.  Jan 2011.
  • PERCAPS – The Development of a “Mother/Child. Screen, Treat and Vaccinate Program” in Diverse High Risk Environments in Peru. Merck Inc. Investigator Initiated Studies Program. $426,919 .00 JL Belinson PI, Feb. 2011
  • CHICAPS – CHINESE CANCER PREVENTION STUDY (CHICAPS)
  • Mass Population Based Cervical Cancer Screening with an Algorithm Based on Self-Sampling for Type Specific High-Risk HPV Using a Community Based Participatory Research Model.   A Collaborative Project under Preventive Oncology International, Peking University Shenzhen Hospital & BGI Shenzhen. Total shared budget – $1,083,316.42   Belinson PI, Wu Co-PI, 2010-2012.
  • CHIMUST – Shenzhen Municipal Science and Technical Innovation Committee (No. JCYJ20120619145419556). Chinese Multi-site Screening Trial. 2015 Belinson Co-PI. 10,000,000 RMB.
  • Shanxi Dayi International Research – 1,000,000 RMB 2017, 2018

Warm thanks go out to all who helped fund our research but were not included in this list.

POI Publications

Below is a (not so brief) list of publications that have directly resulted from, or used data from POI research:

  1. Belinson JL, Qiao YL, Pretorius R, Zhang W, et al.:  Prevalence of Cervical Cancer and Feasibility of Screening in Rural China:  A Pilot Study for the ShanxiProvince Cervical Cancer Screening Study.  Int. J Gynecol Cancer 9:411-417, 1999.
  2. Yang L, Zhang WH, Pan QJ, Li L, Rong SD, Belinson JL, Pretorius RG, Qiao YL.  A pilot study for cervical cancer screening trials in Shanxi Province. Bulletin of Chinese Cancer 2000;9(9): 391-392 (Article in Chinese).
  3. Yang L, Qiao YL, Li N, Zhang X, Kong, LH, Rong SD, Ma JF, Belinson J. Synthesis and cluster analysis for multiple screening techniques for cervical cancer. Cancer Research on Prevention and Treatment 2001;28(4):253-255 (Article in Chinese).
  4. Zhao FH, Li N, Ma JF, Zhang X, Wu LY, Rong SD, Lorincz A, Belinson JL, Qiao YL. Study of the association between human papillomavirus infection and cervical cancer in Xiangyuan County, Shanxi Province. Chin J Epidemiol., October 2001; 22(5):375-378 (Article in Chinese).
  5. Belinson JL, Qiao YL, Pretorius RG, Zhang WH et al:  Shanxi Province Cervical Cancer Screening Study.  A Cross-Sectional Comparative Trial of Multiple Techniques to Detect Cervical Intraepithelial Neoplasia.  Gynecol Oncol 83: 439-44, Nov 2001.
  6. Belinson JL, Qiao YL, Pretorius RG, Zhang WH et al: Cervical Cancer Screening by Simple Visual Inspection after Acetic Acid. Obstetrics and Gynecology 2001; 98:(3),441-444.
  7. Pretorius RG, Belinson JL, Qiao YL, Burchette RJ, Elson P, Zhang WH. Is Colposcopic Impression Influenced by the Colposcopist’s Knowledge of the Result of the Referral Papanicolaou Smear?  J. Repro. Med. 46(8): 724-8, Aug 2001.
  8. Belinson JL,Pan QJ, Biscotti C, Pretorius RG,Elson P, Qiao YL. Primary Screening with Liquid Based Cytology in an Unscreened Population in Rural China, with an Emphasis on Reproducing Unsatisfactory Samples. Acta Cytol. 2002 May-Jun;46(3):470-4.
  9. Rong SD, Chen W, Wu LY, Zhang X, Shen GH, Liu YY, Zhao FH, Ma JF, Qiao YL. Analysis of risk factors for cervical cancer in Xiangyuan County, Shanxi Province. Chinese Journal of Preventive Medicine 2002:36(1):41-43(Article in Chinese).
  10. Pan QJ, Kong LH, Shen GH, Li L, Qiao YL, Zhang WH. Liquid-based cytologic screening compared with HPV testing to detect cervical cancer. Cancer Research on Prevention and Treatment 2002;29(4):303-305 (Article in Chinese).
  11. Tisci  SE, Shen YH, Fife D, Goycoolea JM, Ma CP, Qiao YL, Belinson JL, Huang RD, Qiao YL.Patient acceptance of self-sampling for human papillomavirus in rural china.  J Lower Genital Tract Dis. 2003; 7(2): 107-116.
  12. Shen YH, Chen F, Huang MN, Liu B, Zhao FH, Li SM, Li N, Zhang WH, Rong SD, Wu LY, Ren SD, Huang RD, Qiao YL. Population-based study of HPV infection in high-risk area for cervical cancer in Shanxi Province, China. Acta Acad Med Sin, 2003.25(4): 381-5. (Article in Chinese).
  13. Pan QJ, Belinson JL, Li L, Pretorius RG, Qiao YL, Zhang WH, Zhang X, Wu LY, Rong SD, Sun YT. A Thin-Layer Liquid-Based Pap Test for Mass Screening in an Area of China with a High Incidence of Cervical Carcinoma: A Cross-Sectional Comparative Study. ACTA Cytol. 2003; 47:45-50.
  14. Wu LY, Li N, Zhang WH, Li L, Pan QJ, Qiao YL, Rong SD, Zhao FH, Pretorius RG, Belinson JL.  Value of acetic acid smear test for cervical cancer screening.  Ai Zheng. 2003 Oct; 22(10):  1096-8.  Chinese.
  15. Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, Li L, Fife D. Shanxi Province Cervical Cancer Screening Study II: Self-Sampling for High-Risk Human Papillomavirus Compared to Direct Sampling for HPV and Liquid Based Cervical Cytology. Int. J. Gyn Cancer 2003; 13:1-8.
  16. Escobar PF, Belinson JL, White A, Shakhova N, Feldchtein F, Kareta M, Gladkova N. Diagnostic Efficacy of Optical Coherence Tomography in the Management of Pre-Invasive and Invasive Cancer of the Uterine Cervix and Vulva.  Int. J. Gyn Cancer.  2004-May-Jun; 14(3):470-4.
  17. Li N, Zhang WH, Wu LY, Li AL, Qiao YL, Li L, Pan QJ. Endocervical curretage: an analysis of results in 1997 women. Zhonghua Zhong Liu Za Zhi. 2004 Jul;26(7):406-8 (Article in Chinese).
  18. Zhao FH, Ma JF, Yang XP, Xiang XE, Rong SD, Li L, Zhang WH, Qiao YL, Association between high-risk human papillomavirus DNA load and Cervical intraepithelial lesion. Chin J Epidemiol., October 2004; 25(11):921-924 (Article in Chinese)
  19. Pretorius RG, Belinson JL, Qiao YL, Zhang WH, Li L, Wu LY. “Colposcopically Directed Biopsy, Random Cervical Biopsy, and Endocervical Curettage in the Diagnosis of Cervical Intraepithelial Neoplasia II or worse.” Am. J. OB/GYN, 2004 Aug; 191(2):430-4.
  20. Escobar PF, Rojas-Espaillat L, Belinson JL.  Optical Diagnosis of Cervical Dysplasia.   International Journal of Gynaecology & Obstetrics.  89(1):63-4, April 2005.
  21. Chen F, Shen Y-, Liu B, Pan QJ, Huang MN, Rong SD, Qiao YL. Studies on the detection of human papillomavirus in cervix cancer with hybrid capture II method. Chinese Journal of Medicine. 2005 Jan 12;85(2):129-30. (Article in Chinese).
  22. Zhao FH, Forman MR, Belinson JL, Shen YH, Graubard BI, Patel AC, Rong SD, Pretorius RG, Qiao YL.  Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China.  Int J Cancer. 2006 Jan 15; 118(2):  442-8.
  23. Pretorius RG, Zhang X, Belinson JL, Zhang WH, Ren SD, Bao YP, Qiao YL.  Distribution of cervical intraepithelial neoplasia 2, 3 and cancer of the uterine cervix.  J Low Genit Tract Dis. 2006 Jan; 10(1):  45-50.
  24. Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL.  Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy.  J Low Genit Tract Dis. 2006 Jan; 10(1):  5-9.
  25. Belinson JL.  Are screen-and-treat approaches effective for cervical cancer prevention?  Nat Clin Pract Oncol. 2006 Jun:3(6): 296-7.
  26. Belinson JL.  A randomized trial examining two alternative approaches to cervical cancer screening in low-resource setting (Khayelitsha, South Africa).  Oncology Abstracts Editorial Reviews.  Fall 2006.
  27. Belinson JL.  Screening for cervical cancer in underserved populations.  Abstracts in Hematology & Oncology Editorial Review.  Spring 2006, Vol 9, No. 2.
  28. Escobar PF, Rojas-Espaillat L, Tisci S, Enerson C, Brainard J, Smith J, Tresser NJ, Feldchtein FI, Rojas LB, Belinson JL.  Optical coherence tomography as a diagnostic aid to visual inspection and colposcopy for preinvasive and invasive cancer of the uterine cervix.  Int J Gynecol Cancer.  2006 Sept-Oct; 16(5):  1815-22.
  29. Zhao C, Li J, Tu Z, Song D, Cui SH, Zhang WH, Qiao YL, Wang JL, Belinson JL, Wei LH.  Study on the correlation between human papillomavirus infection and cervical lesion among women living in community of Beijing.  Zhonghua Liu Xing Bing Xue Za Zhi. 2007 Oct; 28 (10): 947-50.  Chinese
  30. Pretorius RG, Belinson JL.  Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer. 2007 Nov 15; 121(10):  2218-24.
  31. Pretorius RG, Belinson JL.  Letter to the editor concerning Petignat et al.’s  “Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing?  A systemic review and meta-analysis.”  Gynecol Oncol 2007; 105(2):  530-535.
  32. Li XL, Wang H, Li CQ, Wu YP, Liu JH, Song D, Liu XF, Qiao YL. [Human papillomaviruses infections among village women in Henan province] Chinese Journal of Preventive Medicine. 2007 Jun;41 Suppl:77-80. Chinese.
  33. Li LY, Qiao ZQ, Zhang MF, Yang JP, Bao YP, An YT, Lei J, Xiong NH, Yu XH, Zhang X, Pan QJ, Qiao YL. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China] Chinese Journal of Epidemiology. 2007 Oct;28(10):964-7. Chinese.
  34. Bao YP, Li N, Wang H, Qiao YL*. [Study on the distribution of human papillomavirus types in cervix among Chinese women: a meta-analysis] Chinese Journal of Epidemiology. 2007 Oct;28(10):941-6. Chinese.
  35. Yang B, MD, Pretorius RG, Belinson JL, Zhang X, Burchette R, Qiao YL. False negative colposcopy is associated with thinner cervical intraepithelial neoplasia 2 and 3.  Gynecol Oncol. 2008 May 15.
  36. Belinson S, Smith JS, Myers E, Olshan A, Belinson JL, Pretorius R, Qiao Y, Hartmann, K.  Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique.  Cancer Epidemiol Biomarkers Prev 2008; 17(9), Sept 2008
  37. Li J, Li LK, Ma JF, Wei LH, Niyazi M, Li CQ, Xu AD, Wang JB, Liang H, Belinson JL, Qiao YL.  Knowledge and attitudes about human papillomavirus (HPV) and HPV vaccines among women living in metropolitan and rural regions of China.  Vaccine. 2009 Feb 18;27 (8): 1210-5.  Epub 2009 Jan. 9.
  38. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, Shi H, Liu JH, Xie X, Niyazi M, Yang P, Wei LH, Li LY, Li J, Liu JF, Zhou Q, Hong Y, Li L, Li Q, Zhou HL, Bian ML, Chen J, Qiao YL*, Smith JS.  Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009 20(9):1705-13.
  39. Zhao FH, Hu SY, Wang SM, Chen F, Zhang X, Zhang WH, Pan QJ, Qiao YL*. Association between high-risk human papillomavirus DNA load and different histological grades of cervical neoplasia. Chinese Journal of Preventive Medicine. 2009 Jul;43(7):565-70. Chinese.
  40. Belinson, JL, Pretorius RG, Enerson C, Garcia F, Perez Cruz E, Belinson S, Yeverino Garcia E, Brainard J.  The Mexican Cervical Cancer Screening Trial (MECCS): Self-Sampling for the Human Papillomavirus with Unaided Visual Inspection as a Secondary Screen.  Int J Gyn Cancer.  2009 Jan; 19(1):27-32.
  41. Shi JF, Belinson JL, Zhao FH, Pretorius RG, Li J, Ma JF, Chen F, Xiang W, Pan QJ, Zhang X, Zhang WH, Qiao YL, Smith JS.  Human papillomavirus testing for cervical cancer screening:  results from a 6-year prospective study in rural China.  Am J Epidemiol. 2009 Sep 15; 170(6):708-16.
  42. Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith J, Li J, Taddeo F, Burchette R, Qiao YL.  Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal, and vaginal self-collected specimens; implications for vaginal self-collection.  Int J Gyn Cancer 2010 Sept 1; 127(5): 1151-7.
  43. Cagle A, Hu S, Sellors J, Bao Y, Lim J, Li S, Lewis K, Song Y, Ma J, Pan Q, Zhang W, Zhao F, Qiao Y*. Use of an expanded gold standard to estimate the accuracy of colposcopy and visual inspection with acetic acid (VIA). Int J Cancer. 2010  Jan 1. 126(1):156-61.
  44. Liu Z, Belinson SE, Li J, Yang B, Wulan N, Tresser NJ, Wang C, Mohr M, Zhang L, Zhou Y, Weng L, Wu RF, Belinson JL. Study of the diagnostic efficacy of “real time” optical coherence tomography (OCT) in the management of pre-invasive neoplasia of the uterine cervix. Int J Gynecol Cancer. 2010 Feb;20(2):283-7.
  45. Wulan N, Rasool N, Belinson SE, Wang C ,Rong X, Zhang W, Zhu YS, Yang B, Tresser NJ,  Mohr M, Wu RF, Belinson JL, . Study of the diagnostic efficacy of “real time” optical coherence tomography (OCT) as an adjunct to unaided visual inspection with acetic acid (VIA) for the diagnosis of pre-invasive and invasive neoplasia of the uterine cervix.  Int J Gynecol Cancer. 2010 Apr;20(3):422-7
  46. Belinson SE, Na W, Ruizhen L, Wei Z, Xuan R, Yasha Z, Wu R, Belinson JL. SNIPER: A novel assay for Human Papillomavirus testing among women in Guizhou, China.  Int J Gynecol Cancer. 2010 Aug;20(6):1006-10
  47. Arriba LN, Enerson CL, Belinson S, Novick L, Belinson J Int J Gynecol Cancer. Mexican Cervical Cancer Screening Study II: acceptability of human papillomavirus self-sampler 2010 Nov;20(8):1415-23.
  48. Ruifang W, Belinson SE, Hui D,Na W, Xinfeng Q, Ruosong W, Ying L, Chun W, Yanqiu Z, Lijie Z, Belinson JL. Human papillomavirus (HPV) mRNA assay for cervical cancer screening:  The Shenzhen Cervical Cancer Screening Trial I (SHENCCAST I). Int J Gynecol Cancer. 2010 Nov;20(8):1411-4
  49. Belinson SE, Belinson JL. Human Papillomavirus DNA Testing for Cervical Cancer Screening: Practical Aspects in Developing Countries. Molecular Diagnosis and Therapy. 2010:14(4), 215-222
  50. Zhao, FH, Lin, MJ, Chen F, Hu Sy, Zhang, R, Belinson JL, Sellors, JW, Franceschi, S, Qiao, YL, Castle, PE. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 populations-based studies from China.  Lancet Oncol. 2011 Jan;12(1):11.
  51. Kang W. Qi X. Tresser NJ. Kareta M. Belinson JL. Rollins AM. Diagnostic efficacy of computer extracted image features in optical coherence tomography of the precancerous cervix. Medical Physics. 38(1):107-13, Jan. 2011
  52. Gravitt PE, Belinson JL, Salmeron J, Shah KV. Looking ahead: a case for HPV testing of self-sampled vaginal specimens 1 as a cervical cancer screening strategy.  Int. J. Cancer: 129, 517–527 (2011).
  53. Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL. Regardless of Skill, Performing More Biopsies Increases the Sensitivity of Colposcopy. J Low Genit Tract Dis. 2011  Jul;15(3):180-8.
  54. Belinson JL, Wu R, Belinson SE, Qu X, Yang B, Du H, Wu R, Wang C, Zhang L, Zhou Y, Liu Y, Pretorius RG.  A Population Based Clinical Trial Comparing Endocervical High-Risk HPV Testing using Hybrid Capture II and Cervista from the SHENCCAST II Study. Am J. Clinical Pathology 2011 May; 135(5):790-5. 
  55. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, Pretorius RG, Yi X, Castle P. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing.  Int J Cancer. 2012 Apr 15;130(8):1855-60
  56. Du H, Yi J, Wu R, Belinson SE, Qu X, Yang B, Wang C, Yi X, Belinson JL.  A New PCR based Mass Spectrometry System for High-Risk HPV Part II – Clinical Trial. Am J Clin Pathol. 2011 Dec;136(6):920-3
  57. Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, Zhang WH, Pan QJ, Zhang X, Belinson JL, Sellors JW, Smith JS, Qiao YL, Franceschi S. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012 Dec 15;131(12):2929-38
  58. Smith JS, Lewkowitz AK, Qiao YL, Ji J, Md SH, Chen W, Md RZ, Liaw KL, Esser M, Taddeo FJ, Pretorius RG, Belinson JL.Population-based human papillomavirus 16,18, 6 and 11 DNA positivity and seropositivity in Chinese women. Int J Cancer. 2012 Sep 15;131(6):1388-95. 
  59. Shi JF, Chen JF, Canfell K, Feng XX, Ma JF, Zhang YZ, Zhao FH, Li R, Ma L, Li ZF, Lew JB, Ning Y,Qiao YL.  Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study.BMC Health Serv Res. 2012 May 24;12:123. 
  60. Belinson SE, Ledford K, Rasool N, Rollins A, Wilan N, Wang C, Rong X, Zhang W, Zhu Y, Tresser N, Wu R, Belinson JL. Cervical Epithelial Brightness by Optical Coherence Tomography Can Determine Histological Grades of Cervical Neoplasia. J Low Genit Tract Dis. 2013 Apr;17(2):160-6
  61. Belinson JL, Pretorius RG. Vaginal Self-Collection in Human Papillomavirus Testing. US Obstetrics and Gynecology (Touch Briefings) 2011; 6(2), 13-15 and Eur Obstetrics and Gynaecology (Touch Briefings) 2012; 7(1), 42-44.
  62. Wu R, Du H, Belinson SE, Pretorius RG, Zou J, Yang B, Wang C, Belinson JL. Secondary screening after primary self-sampling for human papillomavirus from SHENCCAST II. J Low Genit Tract Dis. 2012 Oct;16(4):416-20. 
  63. Ji J, Sun HK, Smith JS, Wang H, Esser MT, Hu S, Pretorius RG, Chen W, Belinson JL, Qiao YL. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women. Infect Dis. 2012 Jun 20;12:137. 
  64. Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, Pan QJ, Ma JF, Niyazi M, Li CQ, Li SM, Smith JS, Belinson JL, Qiao YL, Castle PE. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst. 2012 Feb 8;104(3):178-88.
  65. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy. Int J Cancer. 2013 Jan 1;132(1):101-8. 
  66. Pretorius RG, Belinson JL, Azizi F, Peterson PC, Belinson S. Utility of random cervical biopsy and endocervical curettage in a low-risk population. J Low Genit Tract Dis. 2012 Oct;16(4):333-8. 
  67. Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J. Primary Cervical Cancer Screening and Triage Using an mRNA Human Papillomavirus Assay and Visual Inspection. Int J Gynecol Cancer. 2013 Mar; 23(3):513-8
  68. Levinson KL, Abuelo C, Chyung E, Salmeron J, Belinson SE, Sologuren CV, Ortiz CS, Vallejos MJ, Belinson JL. The Peru Cervical Cancer Prevention Study (PERCAPS): Community-Based Participatory Research in Manchay, Peru. Int J Gynecol Cancer. 2013 Jan;23(1):141-147.
  69. Abuelo CE, Levinson KL, Salmeron J, Sologuren CV, Fernandez MJ, Belinson JL. The Peru Cervical Cancer Screening Study (PERCAPS): the design and implementation of a mother/daughter screen, treat, and vaccinate program in the Peruvian jungle. J Community Health. 2014 Jun;39(3):409-15. doi: 10.1007/s10900-013-9786-6. PMID: 24276617; PMCID: PMC4543313.
  70. Levinson KL, Abuelo C, Chyung E, Salmeron J, Belinson SE,  Sologuren CV, Ortiz CS, Vallejos MJ, Belinson JL. The Peru Cervical Cancer Prevention Study (PERCAPS): The Technology to Make Screening Accessible. Gynecol Oncol. 2013 May;129(2):318-23
  71. Wang SM, Colombara D, Shi JF, Zhao FH,  Li J, Chen F, Chen W, Li SM, Zhang X, Pan QJ, Belinson JL, Smith JS, and Qiao YL. Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses. Int J Gynecol Cancer. 2013 May;23(4):716-23.
  72. CastlePE, de Sanjosé S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine. 2012 Nov 20;30 Suppl 5:F117-22. 
  73. Pretorius RG, Belinson JL. Colposcopy. Minerva Ginecol. 2012 Apr;64(2):173-80. Review.
  74. Starks D, Arriba LN, Enerson CL, Brainard J, Nagore N, Chiesa-Vottero A, Uribe JV, Belinson J. Mexican Cervical Cancer Screening Study II: 6-month and 2-year follow-up of HR-HPV women treated with cryotherapy in a low-resource setting. J Low Genit Tract Dis. 2014 Oct;18(4):333-7. doi: 10.1097/LGT.0000000000000029. PMID: 24977628.
  75. Goodrich SK, Schlegel CR, Wang G, Belinson JL. Use of artemisinin and its derivatives to treat HPV-infected/transformed cells and cervical cancer: a review. Future Oncol. 2014 Mar;10(4):647-54. doi: 10.2217/fon.13.228. PMID: 24754594.
  76. Yi X, Zou J, Xu J, Liu T, Liu T, Hua S, Xi F, Nie X, Ye L, Luo Y, Xu L, Du H, Wu R, Yang L, Liu R, Yang B, Wang J, Belinson JL. Development and validation of a new HPV genotyping assay based on next-generation sequencing. Am J Clin Pathol. 2014 Jun;141(6):796-804. doi: 10.1309/AJCP9P2KJSXEKCJB. PMID: 24838323.
  77. Pan QJ, Hu SY, Zhang X, Ci PW, Zhang WH, Guo HQ, Cao J, Zhao FH, Lytwyn A, Qiao YL.  Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.Cancer Cytopathol. 2013 Sep;121(9):473-82. 
  78. Pretorius RG, Belinson JL, Peterson P, Azizi F, Lo A. Yield and mode of diagnosis of cervical intraepithelial neoplasia 3 or cancer among women with negative cervical cytology and positive high-risk human papillomavirus test results. J Low Genit Tract Dis. 2013 Oct;17(4):430-9. 
  79. Goodrich SK, Pretorius RG, Du H, Wu R, Belinson JL. Triage of Women With Negative Cytology and Positive High-Risk HPV: An Analysis of Data From the SHENCCAST II/III Studies. J Low Genit Tract Dis. 2013 Nov 21. [Epub ahead of print] PubMed PMID: 24270196.
  80. Zhang R, Velicer C, Chen W, Liaw KL, Wu EQ, Liu B, Cui JF, Belinson JL, Zhang X, Shen GH, Chen F, Qiao YL. Human papillomavirus genotype distribution incervical intraepithelial neoplasia grades 1 or worse among 4215 Chinese women in a population-based study. Cancer Epidemiol. 2013 Dec;37(6):939-45. doi:10.1016/j.canep.2013.10.005. Epub 2013 Nov 8. PubMed PMID: 24210584.
  81. Liang LY, Du H, Wang C, Zhang W, Chen Y, Qu XF, Yang B, Wu B, Wu RS, Belinson JL, Wu RF. [Crosssectional survey of human papilloma virus subtype distribution and cervical intraepithelial neoplasia in Shenzhen]. Beijing Da Xue Xue Bao. 2013 Feb 18;45(1):114-8. Chinese. PubMed PMID: 23411532.
  82. Sui S, Jiao Z, Niyazi M, S S, Lu P, Qiao YL.Genotype distribution and behavioral risk factor analysis of human papillomavirus infection in uyghur women.Asian Pac J Cancer Prev. 2013;14(10):5861-5.
  83. Wu EQ, Liu B, Cui JF, Chen W, Wang JB, Lu L, Niyazi M, Zhao C, Ren SD, Li CQ, Gong XZ, Smith JS, Belinson JL, Liaw KL, Velicer C, Qiao YL. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. Cancer Causes Control. 2013 Apr;24(4):795-803. doi: 10.1007/s10552-013-0162-8. Epub 2013 Feb 9. 
  84. Wang H, Wang T, Hu SY, Zhao FH, Zhang X, Pan QJ, Zhang WH, Li L, Qiao YL. Comparison on the predictive values of four screening methods regarding cervical cancer. Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Feb;34(2):191-4. Chinese.
  85. Belinson JL, Wang GX, Qu XF, Du H, Shen JJ, Xu JJ, Zhong LQ, Yi J, Yi X, Wu RF.The Development and Evaluation of a Community Based Model for Cervical Cancer Screening Based on Self-sampling. Gynecol Oncol. 2014 Mar;132(3):636-42. doi: 10.1016/j.ygyno.2014.01.006. Epub 2014 Jan 14
  86. Boers A, Slagter-Menkema L, van Hemel BM, Belinson JL, Ruitenbeek T, Buikema HJ, Klip H, Ghyssaert H, van der Zee AG, de Bock GH, Wisman GB, Schuuring E. Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off. PLoS One. 2014 Jul 22;9(7):e101930. doi: 10.1371/journal.pone.0101930. eCollection 2014.
  87. Pretorius RG, Belinson JL, Peterson P, Burchette RJ. Which Colposcopies Should Include Endocervical Curettage? J Low Genit Tract Dis. 2015 Oct;19(4):278-81. doi: 10.1097/LGT.0000000000000119.PMID: 26083335
  88. Pretorius RG, Belinson JL, Peterson P, Burchette RJ. Factors That Virtually Exclude Cervical Cancer at Colposcopy. J Low Genit Tract Dis. 2015 Oct;19(4):319-22. doi: 10.1097/LGT.0000000000000122. PMID: 26083334.
  89. Zhang L, Du H, Zhang W, Yang B, Wang C, Belinson JL, Wu R. Diagnostic value of multiply biopsies and endocervical curettage on cervical lesions. Zhonghua Fu Chan Ke Za Zhi. 2015 Apr;50(4):263-7. Chinese.
  90. Krishnan S, Sivaram S, Anderson BO, Basu P, Belinson JL, Bhatla N, Cruz AD, Dhillon PK, Gupta PC, Joshi N, Jhulka PK, Kailash U, Kapambwe S, Katoch VM, Kaur P, Kaur T, Mathur P, Prakash A, Sankaranarayanan R, Selvam JM, Seth T, Shah KV, Shastri S, Siddiqi M, Srivastava A, Trimble E, Rajaraman P, Mehrotra R. Using implementation science to advance cancer prevention in India. Asian Pac J Cancer Prev. 2015;16(9):3639-44.
  91. Sewali B, Okuyemi KS, Askhir A, Belinson J, Vogel RI, Joseph A, Ghebre RG. Cervical cancer screening with clinic-based Pap test versus home HPV test among Somali immigrant women in Minnesota: a pilot randomized controlled trial. Cancer Med. 2015 Apr;4(4):620-31. doi: 10.1002/cam4.429. Epub 2015 Feb 4.
  92. Rajaraman P, Anderson BO, Basu P, Belinson JL, , Dhillon PK, Gupta P, Jawahar TS, Joshi N, Kailash U, Kapambwe S, Katoch VM, Krishnan S, Panda D, Sankaranarayanan R, Selvam JM, Shah KV, Shastri S, Shridhar K,  Siddiqi M, Sivaram S, Seth T, Srivastava A, Trimble E, Mehrotra R. Recommendations for screening and early detection of common cancers in India. Lancet Oncol. 2015 Jul;16(7):e352-61. doi: 10.1016/S1470-2045(15)00078-9. Review.
  93. Levinson KL, Jernigan AM, Flocke SA, Tergas AI, Gunderson CC, Huh WK, Wilkinson-Ryan I, Lawson PJ, Fader AN, Belinson JL. Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis. 2016 Jan;20(1):47-51. doi: 10.1097/LGT.0000000000000153.
  94. Zhao J, Du H, Belinson JL, Qu X, Zhang W, Mei J, Yang B, Wang C, Zhang L, Wu R. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer. J Med Screen. 2016 Mar;23(1):38-43. doi: 10.1177/0969141315604863. Epub 2015 Oct 14. PMID: 26466824.
  95. Pretorius RG, Belinson JL, Peterson P, Burchette RJ. Which Colposcopies Should Include Endocervical Curettage? J Low Genit Tract Dis. 2015 Oct;19(4):278-81. doi: 10.1097/LGT.0000000000000119.
  96. Pretorius RG, Belinson JL, Peterson P, Burchette RJ. Factors That Virtually Exclude Cervical Cancer at Colposcopy. J Low Genit Tract Dis. 2015 Oct;19(4):319-22. doi: 10.1097/LGT.0000000000000122.
  97. Zhang L, Du H, Zhang W, Yang B, Wang C, Belinson JL, Wu R. Diagnostic value of multiply biopsies and endocervical curettage on cervical lesions. Zhonghua Fu Chan Ke Za Zhi. 2015 Apr;50(4):263-7. Chinese.
  98. Qing Chen, MD; Hui Du, MD; Robert G. Pretorius, MD; Chun Wang, MD; Bin Yang, MD, PhD; Guixiang Wang, MD; Jinlong Tang, MD; Jerome L. Belinson, MD; Ruifang Wu, MD. High-grade CIN detected by colposcopic directed or random biopsy relative to age, cytology, HPV 16, and lesion size. J Low Genit Tract Dis. 2016 Jul;20(3):207-12. doi: 10.1097
  99.  Arvizo C, Chen Q, Du H, Wang C, Tang J, Yang B, Pretorius RG, Wu R, Belinson JL. p16 Immunohistochemistry in Colposcope-Directed and Random Cervical Biopsies of CIN2 and CIN3. J Low Genit Tract Dis. 2016 Jul;20(3):197-200. doi: 10.1097/LGT.0000000000000181. PMID: 26855142.
  100. Kathryn Maurer MD, Hongxue Luo MD, Zhiyong Shen PhD, Guixiang Wang MD, Hui Du MD, Chun Wang MD, Xiaobo Liu MS, Zhihong Liu, Lijie Zhang, Yanqiu Zou, Xinfeng Qu MD, Ruifang Wu MD, and Jerome Belinson MD. The Development and Evaluation of a New Solid Media Specimen Transport Card for Population Based Cervical Cancer Prevention. J Clin Virol. 2016 Mar;76:14-9. doi: 10.1016/j.jcv.2015.12.010. Epub 2016 Jan 2.
  101. Hongxue Luo, Hui Du, Kathryn Maurer, Jerome L. Belinson, Guixiang Wang, Zhihong Liu, Lijie Zhang, Yanqiu Zhou, Chun Wang, Jinlong Tang, Xinfeng Qu, Ruifang Wu. An evaluation of the Cobas4800 HPV test on cervico-vaginal specimens in liquid versus solid transport media. PLoS One. 2016 Feb 1;11(2):e0148168. doi: 10.1371/journal.pone.0148168. eCollection 2016.
  102. Ma’som M, Bhoo-Pathy N, Nasir NH, Bellinson J, Subramaniam S, Ma Y, Yap SH, Goh PP, Gravitt P, Woo YL. Attitudes and factors affecting acceptability of self-administered cervicovaginal sampling for human papillomavirus (HPV) genotyping as an alternative to Pap testing among multiethnic Malaysian women. BMJ Open. 2016 Aug 4;6(8):e011022. doi: 10.1136/bmjopen-2015-011022. PMID: 27491667; PMCID: PMC4985871
  103. Liu C, Du H, Wang C, Belinson JL, Yang B, Zhang W, Tang J, Wu R. HPV L1 and P16 Expression in CIN1 to Predict Future CIN2. Int J Gynecol Pathol. 2017 May;36(3):281-288. doi: 10.1097/PGP.0000000000000326. PMID: 28277314.
  104. Jin XW, Lipold L, Foucher J, Sikon A, Brainard J, Belinson J, Schramm S, Nottingham K, Hu B, Rothberg MB. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years. J Gen Intern Med. 2016 Jul 14.
  105. Belinson JL, Pretorius RG. A Standard Protocol for the Colposcopy Exam. J Low Genit Tract Dis. 2016 Oct;20(4):e61-2. doi: 10.1097J.
  106. M. Arbyn, L. Xu, F. Verdoodt, J. Cuzick, A. Szarewski, J.L. Belinson, Wentzensen, J.C. Gage, M.J. Khan. Genotyping for HPV16 and HPV18 in women with minor cytologic abnormalities: a systematic review and meta-analysis. Ann Intern Med. 2017 Jan 17;166(2):118-127. doi: 10.7326/M15-2735. Epub 2016 Nov 15
  107. Pretorius RG1, Belinson JL. When Should Endocervical Curettage Be Done? J Low Genit Tract Dis. 2016 Apr;20(2):189. doi: 10.1097/LGT.0000000000000180.
  108. Hongxue Luo, MD; Jerome L. Belinson, MD; Hui Du, MD; Zhihong Liu, MD; Lijie Zhang, MD; Chun Wang, MD; Xinfeng Qu, MD; Robert G. Pretorius, MD; Ruifang Wu, MD.  Evaluation of Viral Load as a Triage Strategy with Primary High-risk HPV Cervical Cancer Screening. J Low Genit Tract Dis. 2017 Jan;21(1):12-16. doi: 10.1097/LGT.0000000000000277.
  109. Su Pei Khoo , Nirmala Bhoo-Pathy , Siew Hwei Yap , Mohd Khairul Anwar Shafii,  Nazrila Hairizan Nasir, Jerome Belinson , ShriDevi Subramaniam, Pik Pin Goh, Ming Zeng, Hong Dong Tan,  Patti Gravitt, Yin Ling Woo. The prevalence and socio-demographic correlates of cervico-vaginal human papillomavirus (HPV) carriage in a cross sectional multi-ethnic community-based female Asian population. Sex Transm Infect. 2017 Nov 27. pii: sextrans-2017-053320. doi: 10.1136/sextrans-2017-053320.
  110. Smith JS, Des Marais AC, Deal AM, Richman AR, Perez-Heydrich C, Yen-Lieberman B, Barclay L, Belinson J, Rinas A, Brewer NT. Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States. Sex Transm Dis. 2017 Jul 26. doi: 10.1097/OLQ.0000000000000681
  111. Wu S, Sun J, Lv H, Zhang Y2, Shang H, Zhang H, Belinson JL Pregnancy in a woman with untreated bladder exstrophy: a case report. Case Rep. Womens Health. 2018 Mar 10;17:11-13. doi: 10.1016/j.crwh.2018.02.002. eCollection 2018 Jan; 17:11-13.
  112. Belinson JL, Pretorius RG, Qu X. Letter to the editor: Cervical Screening by Pap Test and Visual Inspection Enabling Same-Day Biopsy in Low-Resource, High-Risk Communities.Obstet.Gynecol.2019:Mar;133(3):583.doi:10.1097/AOG.0000000000003147
  113. Hongxue Luo, Hui Du, Jerome L. Belinson, Ruifang Wu. Evaluation of alternately combining HPV viral load and 16/18 genotyping in secondary screening algorithms. PLoS One. 2019; 14(7): e0220200. Published online 2019 Jul 26. doi: 10.1371/journal.pone.0220200 PMCID: PMC6660090
  114. Robert G Pretorius, Jerome L Belinson, Raoul J Burchette, Ruifang Wu, You-Lin Qiao. Key Determinants of the Value of Random Cervical Biopsy at Colposcopy. J Low Genit Tract Dis. 2019 Oct;23(4):241-247. doi: 10.1097/LGT.0000000000000485
  115. Wei Zhang, Hui Du, Xia Huang, Chun Wang, Xianzhi Duan, Yan Liu, Bin Shi, Wei Zhang, Xinfeng Qu, Lihui Wei, M. Schiffman, J. L. Belinson, Ruifang Wu. Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening. Infect Agent Cancer. 2020; 15: 65. Published online 2020 Oct 23. doi: 10.1186/s13027-020-00328-1 PMCID: PMC7583687.
  116. Kayode Olusegun Ajenifuja, Jerome Belinson, Andrew Goldstein, Kanan T. Desai, Silvia de Sanjose, Mark Schiffman. Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self sampled HPV typing. Infect Agent Cancer. 2020; 15: 61. Published online 2020 Oct 14. doi: 10.1186/s13027-020-00325-4 PMCID: PMC7556607
  117. Fangbin Song, Hui Du, Aimin Xiao, Chun Wang, Xia Huang, Peisha Yan, Zhihong Liu, Xinfeng Qu, Jerome L. Belinson, Ruifang Wu. Evaluating the Performance of p16 Immunocytochemistry in Cervical Cancer Screening. Cancer Manag Res. 2020; 12: 9067–9075. Published online 2020 Sep 25. doi: 10.2147/CMAR.S273079 PMCID: PMC7524171.
  118. Lyufang Duan, Hui Du, Chun Wang, Xia Huang, Xinfeng Qu, Bin Shi, Yan Liu, Wei Zhang, Xianzhi Duan, Lihui Wei, Jerome L. Belinson, Ruifang Wu. The effectiveness of HPV viral load, reflected by Cobas 4800 HPV-Ct values for the triage of HPV-positive women in primary cervical cancer screening: Direct endocervical samples. PLoS One. 2020; 15(5): e0232107. Published online 2020 May 7. doi: 10.1371/journal.pone.0232107 PMCID: PMC7205204.
  119. Jingfen Sun MD, Suhui Wu MD PhD, Longhua Hu MD, Haixia Shang MD, PhD, Yufeng Yang BS, Robert Pretorius MD, Yaling Huang BS, Xi Yang, MD, MS, Xiaoqin Wu BS, Jerome Belinson MD.  Evaluation of liquid vs. dry specimen transport with a newly validated isothermal amplification HR-HPV Assay. J Low Gent Tract Dis 2020;24:243-246.
  120. Jerome L. Belinson MD, Robert G. Pretorius MD, Ruifang Wu, MD. The Ampfire HPV Technology. HPV World. www.HPVworld.com. 2020; no. 119.
  121. Philip E Castle, Amanda J Pierz, Rachael Adcock, Shagufta Aslam, Partha S Basu, Jerome L Belinson, Jack Cuzick, Mariam El-Zein, Catterina Ferreccio, Cynthia Firnhaber, Eduardo L Franco, Patti E Gravitt, Sandra D Isidean, John Lin, Salaheddin M Mahmud , Joseph Monsonego, Richard Muwonge, Samuel Ratnam, Mahboobeh Safaeian, Mark Schiffman, Jennifer S Smith, Avril Swarts, Thomas C Wright, Vanessa Van De Wyngard , Long Fu Xi.  A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus-positive and -Negative Cervical Precancers. Cancer Prev Res. 2020 Oct;13(10):829-840. doi: 10.1158/1940-6207.CAPR-20-0182. Epub 2020 Jul 12.
  122. Fangbin Song, Hui Du, Chun Wang, Xia Huang, Xinfeng Qu, Lihui Wei, Jerome L Belinson, Ruifang Wu, CHIMUST team. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening.  J. Med. Screening. 2021. Sept. 28(3):318-324. https://doi.org/10.1177/0969141320943634
  123. Duan L, Du H, Belinson JL, Liu Z, Xiao A, Liu S, Zhao L, Wang C, Qu X, Wu R. Thermocoagulation versus cryotherapy for the treatment of cervical precancers. J Obstet Gynaecol Res. 2021 Jan;47(1):279-286. doi: 10.1111/jog.14520. Epub 2020 Oct 21.
  124. Robert G Pretorius, Jerome L Belinson, Patricia Peterson. Loop Electrosurgical Excision Procedure or Cervical Conization to Exclude Cervical Cancer Before Simple Hysterectomy. J Low Genit Tract Dis. . 2020 Apr;24(2):202-205. doi: 10.1097/LGT.0000000000000519.
  125. Du, Hui; Duan, Xianzhi; Liu, Yan; Shi, Bin; Zhang, Wei; Wang, Chun; Qu, Xinfen; Bao, Juncui; Li, Jingran; Zhao, Chao; Jiang, Jing; Liu, Juan; Wu, Kejia; Xiao, Aimin; Duan, Lvfang; Huang, Xia; Bian, Shuhuang; Zhang, Lijie; Luo, Hongxue; Wei, Lihui; Belinson, Jerome L.; Wu, Ruifang. An evaluation of solid versus liquid transport media for high-risk HPV detection and cervical cancer screening on self-collected specimens Infectious Agents and Cancer, 2020, 15(1): 72.
  126. Song FB, Du H, Xiao AM, Wang C, Huang X, Yan PS, Liu ZH, Qu XF, Belinson Jerome L, Wu RF. Zhonghua Fu Chan Ke Za Zhi. [Clinical value of p16INK4a immunocytochemistry in cervical cancer screening]. 2020 Nov 25;55(11):784-790.
  127. Pretorius RG, Belinson JL. Re: An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. J Natl Cancer Inst. 2020 Jan 1;112(1):114.
  128. Du H, Duan X, Liu Y, Shi B, Zhang W, Wang C, Qu X, Li J, Zhao C, Liu J, Jiang J, Jin H, Li H, Xiao A, Bao J, Duan L, Huang X, Luo H, Bian S, Zhang L, Wei L, Belinson JL, Wu R. Evaluation of Cobas HPV and SeqHPV Assays in the Chinese Multicenter Screening Trial. J Low Genit Tract Dis. 2021 Jan 1;25(1):22-26.
  129. Khoo SP, Shafii MKA, Bhoo-Pathy N, Yap SH, Subramaniam S, Nasir NH, Lin Z, Belinson J, Goh PP, Qu X, Gravitt P, Woo YL. Prevalence and sociodemographic correlates of anogenital Human Papillomavirus (HPV) carriage in a cross-sectional, multi-ethnic, community-based Asian male population. PLoS One. 2021 Jan 20;16(1)
  130. Guo C, Du H, Belinson JL, Wang C, Huang X, Qu X, Wu R; CHIMUST team. Infect Agent Cancer. The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women. 2021 Mar 25;16(1):21.
  131. Pretorius RG, Belinson JL. Comments on: Cervical cancer prevention in El Salvador: A prospective evaluation of screening and triage strategies incorporating high-resolution microendoscopy to detect cervical precancer. Int J Cancer. 2021 Apr 4. doi: 10.1002/ijc.33587. Epub ahead of print. PMID: 33817788.
  132. Du H, Luo H, Wang C, Qu X, Belinson JL, Wu R. The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features. J Clin Epidemiol. 2021 Jun 20: S0895-4356(21)00187-6.
  133. Song F, Belinson JL, Yan P, Huang X, Wang C, Du H, Qu X, Wu R. Evaluation of p16INK4a immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China. Gynecol Oncol. 2021 Aug;162(2):322-330.
  134. Guo CL, Luo HX, Wang C, Qu XF, Yang B, Belinson JL, Du H, Wu RF. Zhonghua Fu Chan Ke Za Zhi. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening]. 2021 Apr 25;56(4):271-279. doi: 10.3760/cma.j.cn112141-20200824-00357.
  135. LonghuaHu, SuhuiWu, HaixiaShang, JeromeBelinson, JinhongLi, XiaoqinWu, YalingHuang, JingfenSun.Evaluation of dry specimen transport and processing time using an isothermal amplification high-risk human papillomavirus assay. Obstet. Gynecol. Clinical Medicine. https://doi.org/10.1016/j.gocm.2022.01.009
  136. Qing Yang, Hui Du, Xinfeng Qu, Wenkui Dai, Liming Gui, Changzhong Li, Chun Wang, Chunlei Guo, Yi Zhang, Lihui Wei, J. L. Belinson and Ruifang Wu. Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening.  Front. Public Health, Sec. Infectious Diseases: Epidemiology and Prevention; 10 November 2022. https://doi.org/10.3389/fpubh.2022.1010066
  137. Chunlei Guo, Hui Du, Xinfeng Qu, Xianzhi Duan, Jingran Li, Ruizhen Li, Hua Jin, Chun Wang, Chao Zhao, Juncui Bao, Hongxue Luo, Lihui Wei, J L Belinson, Ruifang Wu. Prevalence of Human Papillomavirus Among Chinese Han and Mongols Minority Women in Inner Mongolia, China: Reflected by Self-Collected Samples in CHIMUST. Front. Public Health. 2022 May 25; 840879.
  138. Grace X Ma, Lin Zhu, Shumenghui Zhai, Timmy R Lin, Yin Tan, Cicely Johnson, Carolyn Y Fang, Jerome L Belinson, Min Qi Wang. Empowering Low-Income Asian American Women to Conduct Human Papillomavirus Self-Sampling Test: A Community-Engaged and Culturally Tailored Intervention. Cancer Control. 2022 Jan-Dec; 29:10732748221076813
  139. Michener CM, Ricci S, AlHilli M, Beffa L, Debernardo R, Waggoner SE, Brainard J, Plesa M, Belinson JL, Trimble CL. Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3. Gynecol Oncol. 2023 Oct 13;178:102-109. doi: 10.1016/j.ygyno.2023.10.003. Epub ahead of print. PMID: 37839312.
  140. Jerome Belinson, Robert Pretorius, Ruifang Wu, Youlin Qiao. Preventive Oncology International: A brief history of HPV self-collected vaginal specimens for cervical cancer screening. Gyn and Obs Clin. Med. 3(2023) 144-148.
  141. Du H, Qu X, Wang G, Guo C, Wang Z, Min J, Liu Z, Hu Q, Luo H, Wang C, Huang X, Chen Y, Wu B, Belinson JL, Wu R. Application an internet facilitation in a community-based cervical cancer screening project. BMC Womens Health. 2023 Dec 1;23(1):641. doi: 10.1186/s12905-023-02733-1. PMID: 38041116; PMCID: PMC1069098
  142. Jun Hou, Jerome L Belinson, Hui Du, Changzhong Li, Wei Zhang, Lijie Zhang,                                                  Yi Zhang, Xinfeng Qu , Ruifang Wu. AmpFire HPV and ScreenFire RS HPV Validation Trial. Online publication February 2024, future in-print Am. J. Clin. Pathology.
  143. Dai W, Guo C, Yang Q, Zhang Y, Wu D, Wang C, Belinson JL, Li C, Du H, Qu X, Wu R. Validation of the 2019 American Society of Colposcopy and Cervical Pathology Online Cervical Cancer Screening Program via 9 Large-Cohort Data of Chinese Women. J Low Genit Tract Dis. 2024 Oct 22. doi: 10.1097/LGT.0000000000000852. Epub ahead of print. PMID: 39436316.
  144. Reiter PL, Shoben AB, Cooper S, Ashcraft AM, McKim Mitchell E, Dignan M, Cromo M, Walunis J, Flinner D, Boatman D, Hauser L, Ruffin MT, Belinson JL, Anderson RT, Kennedy-Rea S, Paskett ED, Katz ML. A Mail-Based HPV Self-Collection Program to Increase Cervical Cancer Screening in Appalachia: Results of a Group Randomized Trial. Cancer Epidemiol Biomarkers Prev. 2024 Oct 24. doi: 10.1158/1055-9965.EPI-24-0999. Epub ahead of print. PMID: 39445831
  145. Wang J, Imade G, Akanmu AS, Musa J, Anorlu R, Zheng Y, Garcia-Bedoya O, Sanchez GI, Belinson J, Kim K, Maiga M, Gursel DB, Sagay AS, Ogunsola FT, Murphy RL, Hou L. Analytic performance of ScreenFire HPV RS assay Zebra BioDome format and its potential for large-scale population HPV screening. Infect Agent Cancer. 2024 Nov 29;19(1):59. doi: 10.1186/s13027-024-00622-2. PMID: 39614290; PMCID: PMC11606105.
  146. Haixia Shang,Jingfen Sun,Suhui Wu,Longhua Hu,Xianmei Cui,Jinhong Li, Jerome Belinson, Yaling Huang, Yufeng Yang, Xi Yang, Xinfeng Qu, Juan Felix, Montserrat Soler, Karla Alfaro, Raul Murillo, Ana C. de Uriarte, Miriam Cremer.  Increased vasovagal reactions from randomized cervical ablative treatments in Chinese patients. Accepted 11/2024 Cancer Plus.
  147. Jerome L Belinson MD Why Self-collection is the Means to Maximize Cervical Cancer Screening. . Clinical Laboratory Products, Jan. 31, 2025.
  148. Wang J, Imade G, Akanmu AS, Musa J, Anorlu R, Zheng Y, Joyce B, Adewole I, Morhason-Bello IO, Belinson J, Maiga M, Gursel DB, Sagay AS, Ogunsola FT, Murphy RL, Hou L. Analytical performance of the ScreenFire HPV RS Zebra BioDome assay on four different qPCR platforms. Infect Agent Cancer. 2025 Apr 30;20(1):28. doi: 10.1186/s13027-025-00651-5. PMID: 40307888; PMCID: PMC12042583.
Scroll to Top